Urinary Incontinence - Pipeline Review, H1 2018

SKU ID : GMD-GMDHC10119IDB 10961637

Publishing Date : 30-Jan-2018

No. of pages : 71

PRICE
2000
6000


  • Urinary Incontinence - Pipeline Review, H1 2018

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2018, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

    Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
    - The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on